ASX Announcements

Results of General Meeting held virtually on 28 April 2022, with all resolutions passed on a poll.

Proposed issue of options (LCTOA) as compensation for changes to rights issue pricing.

Cleansing Notice under Section 708AA(2)(f) of the Corporations Act 2001 (Cth).

Living Cell Technologies (ASX:LCT) has advanced plans for a third clinical trial of NTCELL in Parkinson’s disease, following the signing of a Research Agreement with the University of Technology Sydney (UTS) and the Australian Foundation for Diabetes Research (AFDR). The UTS agreement will allow university facilities to be used to optimise the production of NTCELL in Australia for the first time, prior to the third clinical trial. 

Living Cell Technologies Limited is convening a General Meeting of Shareholders, to be held virtually on Thursday, 28 April 2022 at 12:00pm (AEST). Due to the coronavirus pandemic and related issues, the Meeting will be held virtually via a live Zoom teleconference, supported by the Company’s Share Registrar, Computershare.